This protocol addresses newly diagnosed immune thrombocytopenia (ITP) in adult patients aged 18 years and older, establishing the recommended first-line treatment approach for this population.
Adults (age ≥18 years) with immune thrombocytopenia (ITP) presenting for initial therapy.
Initial management involves a short course of corticosteroid therapy, with course duration limited to no more than 6 weeks. The full protocol specifies agent selection and all associated clinical details.
The primary target is platelet count response at 7 days. Prioritising the speed of that response may influence which corticosteroid option is selected.
In adults with newly diagnosed ITP, the ASH guideline panel recommends against a prolonged course (>6 weeks) of prednisone in favor of a short course (≤6 weeks) and suggests either prednisone (0.5–2.0 mg/kg/day) or dexamethasone (40 mg/day for 4 days) as the type of corticosteroid for initial therapy.
If a high value is placed on rapidity of platelet count response, an initial course of dexamethasone may be preferred over prednisone, given that dexamethasone increases the likelihood of a platelet count response at 7 days.
View source ↗